Enzalutamide
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bladder Cancer
Conditions
Bladder Cancer
Trial Timeline
Jan 1, 2016 → Feb 1, 2018
NCT ID
NCT02605863About Enzalutamide
Enzalutamide is a phase 2 stage product being developed by Astellas Pharma for Bladder Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT02605863. Target conditions include Bladder Cancer.
What happened to similar drugs?
10 of 20 similar drugs in Bladder Cancer were approved
Approved (10) Terminated (1) Active (9)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05404139 | Phase 2 | Recruiting |
| NCT02749903 | Phase 2 | Active |
| NCT02799745 | Phase 2 | Completed |
| NCT02750358 | Phase 2 | Active |
| NCT02605863 | Phase 2 | Terminated |
| NCT02384382 | Phase 2 | Completed |
| NCT02441517 | Approved | Terminated |
| NCT02507570 | Phase 2 | Completed |
| NCT02495974 | Pre-clinical | Completed |
| NCT02203695 | Phase 2 | Completed |
| NCT02288936 | Phase 2 | Completed |
| NCT02669771 | Pre-clinical | Completed |
| NCT02124668 | Phase 2 | Completed |
| NCT03297385 | Phase 2 | Completed |
| NCT02116582 | Approved | Completed |
| NCT02099864 | Phase 2 | Completed |
| NCT01977651 | Approved | Completed |
| NCT02138162 | Phase 1 | Completed |
| NCT01889238 | Phase 2 | Completed |
| NCT01663415 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Bladder Cancer